 |
|
Heterogeneous Phenotype in a Family With Compound Heterozygous Parkin Gene Mutations
Hao Deng, PhD;
Wei-Dong Le, MD, PhD;
Christine B. Hunter, RN;
William G. Ondo, MD;
Yi Guo, MS;
Wen-Jie Xie, MD;
Joseph Jankovic, MD
Arch Neurol. 2006;63:273-277.
Background Mutations in the parkin gene (PRKN) cause autosomal recessive early-onset Parkinson disease (EOPD).
Objective To investigate the presence of mutations in the PRKN gene in a white family with EOPD and the genotype-phenotype correlations.
Design Twenty members belonging to 3 generations of the EOPD family with 4 affected subjects underwent genetic analysis. Direct genomic DNA sequencing, semiquantitative polymerase chain reaction, real-time quantitative polymerase chain reaction, and reverse-transcriptase polymerase chain reaction analyses were performed to identify the PRKN mutation.
Results Compound heterozygous mutations (T240M and EX 5_6 del) in the PRKN gene were identified in 4 patients with early onset (at ages 30-38 years). Although heterozygous T240M and homozygous EX 5_6 del mutations in the PRKN gene have been previously described, this is, to our knowledge, the first report of these mutations in compound heterozygotes. The phenotype of patients was that of classic autosomal recessive EOPD characterized by beneficial response to levodopa, relatively slow progression, and motor complications. All heterozygous mutation carriers (T240M or EX 5_6 del) and a 56-year-old woman who was a compound heterozygous mutation carrier (T240M and EX 5_6 del) were free of any neurological symptoms.
Conclusions Compound heterozygous mutations (T240M and EX 5_6 del) in the PRKN gene were found to cause autosomal recessive EOPD in 4 members of a large white family. One additional member with the same mutation, who is more than 10 years older than the mean age at onset of the 4 affected individuals, had no clinical manifestation of the disease. This incomplete penetrance has implications for genetic counseling, and it suggests that complex gene-environment interactions may play a role in the pathogenesis of PRKN EOPD.
Author Affiliations: Department of Neurology, Baylor College of Medicine, Houston, Tex (Drs Deng, Le, Ondo, Xie, and Jankovic and Ms Hunter); and School of Medical Technology and Information, Central South University, Changsha, China (Ms Guo).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Are Parkinson disease patients protected from some but not all cancers?
Inzelberg and Jankovic
Neurology 2007;69:1542-1550.
ABSTRACT
| FULL TEXT
A Family With Parkinson Disease, Essential Tremor, Bell Palsy, and Parkin Mutations
Deng et al.
Arch Neurol 2007;64:421-424.
ABSTRACT
| FULL TEXT
|
